Gammar^®-P I.V.

Immune Globulin Intravenous (Human)

Gammar^®-P I.V. is indicated for patients with primary defective antibody synthesis such as agammaglobulinemia or hypogammaglobulinemia, who are at increased risk of infection.

The First and Only Pasteurized* IGIV

• Unique, patented pasteurization* technique provides added safety
• Pasteurization* has been shown to inactivate both lipid-enveloped and certain non-lipid-enveloped
• Pasteurization* does not significantly impact overall antibody titers¹
• All IgG subclasses are represented

Gammar^®-P I.V. is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin intramuscular or intravenous preparations or in individuals with a history of allergic reactions to human albumin.

Gammar^®-P I.V. should not be given to persons with isolated immunoglobulin A (IgA) deficiency. Such persons have the potential for developing anitbodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

As with all plasma-derived products, the risk of transmission of infectious agents, including viruses, cannot be completely eliminated. As with any pharmaceutical, the physician should weigh the risks and benefits of administration.

*Heat treatment in aqueous solution at 60°C for 10 hours

Full Prescribing Information for Gammar^®-P I.V. with boxed WARNING on acute renal failure